Custom-Made DNA vaccine takes on advanced liver cancer
NCT ID NCT04251117
First seen Apr 29, 2026 · Last updated May 21, 2026 · Updated 3 times
Summary
This study tests a personalized DNA vaccine (made from a patient's own tumor mutations) combined with an immune booster and an immunotherapy drug (pembrolizumab) in 36 adults with advanced liver cancer (HCC). The goal is to see if the vaccine is safe and can train the immune system to attack the cancer. This is an early-stage trial (Phase 1/2a) focused on safety and immune response, not a cure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HCC are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Auckland Clinical Studies
Auckland, New Zealand
-
Icahn School of Medicine at Mount Sinai
New York, New York, 10029, United States
-
Johns Hopkins Hospital
Baltimore, Maryland, 21287, United States
Conditions
Explore the condition pages connected to this study.